The Cytel Blog: Perspectives on Enquiry & Evidence

The promising zone design is an adaptive design which allows for sample size re-estimation based on the results of an..

Despite the debate in the scientific community on adaptive sample size reassessment (SSR), noteworthy developments have..

Methods involving Group Sequential Designs is one of the earliest deviations from a traditional two-arm clinical trial..

On Friday September 11, Cyrus Mehta, co-founder of Cytel, will be delivering a talk to the Heart Failure Collaboratory,..

Cytel is conducting a webinar series that introduces biostatisticians to some of the more commonly used complex..

In this blog, we speak with Christopher Jennison, Professor of Statistics at the University of Bath, UK. Professor..

  A 2018 publication in the  Biometrical Journal by Cytel’s Cyrus Mehta, Lingyun Liu and Sam Hsiao, ‘Optimal Promising..

Cytel biostatisticians Cyrus Mehta and Lingyun Liu, together with Charles Theuer, CEO of TRACON Pharmaceuticals have..

  On August 29th 2018, the FDA announced (1) that it would be establishing a Complex Innovative Trial Design (CID)..